Shots:

• The approval is based on P-III CASPIAN trial assessing Imfinzi + SoC (etoposide & carboplatin/ cisplatin CT) or Imfinzi + CT + tremelimumab vs CT alone in 805 patients with ES-SCLC in 200 centers across 23 countries
• Results: the study met its 1EPs of OS in Jun’19- demonstrating a 27% reduction in risk of death with m-OS (13.0 vs 10.3mos.); ORR (68% vs 58%). An updated analysis demonstrated sustained efficacy after a median follow up 2+ yrs. with m-OS (12.9 vs 10.5mos.)- alive patients (22.2% vs 14.4%) @24mos.- safety & efficacy results were consistent with results in the overall global trial population
• Imfinzi is a mAb targeting PD-L1 & blocks interaction of PD-L1 with PD-1 & CD80

  Ref: AstraZeneca | Image: Mint